… In metastatic colorectal cancer disease progression correlates with serum VEGF levels. The
… of using bevacizumab in the first-line treatment setting for metastatic colorectal cancer was …

… One study evaluating safety of bevacizumab for older colorectal cancer patients found that
use of … (OCS), investigating the use of first‐line bevacizumab for metastatic CRC, has included …

… lacks clinical and molecular biomarkers that correlate with treat… or cetuximab in the first-line
setting were compared. This … left-sided tumors treated with either bevacizumab- or cetuximab…

… a positive correlation between hypertension after bevacizumab treatment and clinical outcome
(Scartozzi et … In fact, TTF of patients who received bevacizumab as first-line or second-line …

… 85 years and correlated with potential prognostic factors. … suggests underutilisation of
bevacizumab in older patients, but … ) of patients aged ≥ 65 years received first-line chemotherapy …

… the start of first-line bevacizumab in patients treated with the … with aflibercept in real-world
clinical practice were consistent … a positive correlation between PFS on bevacizumab and PFS …

… and an anti-EGFR agent with chemotherapy should not be used in patients treated in first
line with mCRC. Ongoing studies continue to evaluate the role of this strategy in more …

… colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus
… plus chemotherapy beyond first progressive disease correlated with prolonged survival …

… -BV had comparable PFS and OS, similar to results in patients with high baseline tumor
ERCC1 levels. There were no new safety signals with these bevacizumab-containing regimens. …

… In fact, bevacizumab was studied in diverse combinations of … in first-line treatment of metastatic
colorectal cancer, ie, … studies assessed the correlation between bevacizumab and tumor …